PPT1 and colonic neoplasm: Their study employed DC661, a selective inhibitor of palmitoyl-protein thioesterase 1 (PPT1), which led to lysosomal membrane permeabilization (LMP) and subsequent release of DAMPs in melanoma and colon cancer models.